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Aconitines, including bulleyaconitine A, probably the most bioactive and abundant
alkaloids in Aconitum plant, are a group of diester C19-diterpenoid alkaloids with one
acetylester group attached to C8 of the diterpenoid skeleton and one benzoylester
group to C14. Hydrolysis of both groups is involved in the processing of Aconitum, a
traditional Chinese medicinal approach. We recently demonstrated that bulleyaconitine
A produced anti-hypersensitivity, which was mediated by stimulation of spinal microglial
dynorphin A expression. This study aimed to elucidate whether the acetylester and
benzoylester groups are involved in aconitine-induced dynorphin A expression, anti-
hypersensitivity, neurotoxicity in neuropathic rats. Intrathecal administration of aconitine
and benzoylaconine (but not aconine) attenuated mechanical allodynia and heat
hyperalgesia, with normalized ED50 values of 35 pmol and 3.6 nmol, respectively.
Aconitine and benzoylaconine anti-allodynia was completely blocked by the microglial
inhibitor, dynorphin A antiserum, and κ-opioid receptor antagonist. Aconitine and
benzoylaconine, but not aconine, stimulated dynorphin A expression in cultured primary
spinal microglia, with EC50 values of 32 nM and 3 µM, respectively. Intrathecal aconitine,
benzoylaconine and aconine induced flaccid paralysis and death, with normalized TD50
values of 0.5 nmol, 0.2 µmol, and 1.6 µmol, respectively. The TD50/ED50 ratios of
aconitine and benzolyaconine were 14:1 and 56:1. Our results suggest that both
the C8-acetyl and C14-benzoyl groups are essential for aconitine to stimulate spinal
microglial dynorphin A expression and subsequent anti-hypersensitivity, which can be
separated from neurotoxicity, because both benzoylaconine and aconine differentially
produced anti-hypersensitivity and neurotoxicity due to their different stimulatory ability
on dynorphin A expression. Our results support the scientific rationale for Aconitum
processing, but caution should be taken to avoid overprocessing and excess hydrolysis
of benzolyaconine to aconine.
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INTRODUCTION
Aconitum is widely prescribed in China and other Eastern
Asia countries for its therapeutic efficacy against nociception,
inflammation, rheumatism, and cardiologic and neurologic
disorders (Chen and Liang, 1982; Hikino et al., 1983; Chen
et al., 2008). Approximately 170 alkaloids have been identified in
Aconitum and classified into four categories: bis-, C20-, C19-, and
C18-diterpenoid alkaloids (Ameri, 1998; Chodoeva et al., 2013).
Aconitines, including aconitine, mesaconitine, hypaconitine,
bulleyaconitine A, yunaconitine, and 3-acetylaconitine, are
probably the most abundant and bioactive C19-diester
diterpenoid alkaloids identified in Aconitum. Aconitine, with
two hydroxyl groups at the C3 and C15 of the skeleton, shares
a very similar structure to bulleyaconitine A (Li et al., 2016).
For C19-diester diterpenoid alkaloids, one acetylester group is
attached to the C8 while another benzoylester group is attached
to the C14. It is generally accepted that both the C-8 acetylester
and C-14 benzoylester are required for aconitines to produce
antinociceptive and neurotoxic effects (Friese et al., 1997; Gutser
et al., 1998; Bello-Ramirez and Nava-Ocampo, 2004a,b). It
has been claimed that the interactions with neuronal sodium
channels were responsible for the analgesic and neurotoxic
effects of aconitines (Ameri, 1998; Gutser et al., 1998; Wang
et al., 2007; Wang et al., 2008; Chan, 2009; Chodoeva et al.,
2013). By quantitative structure-activity relationship analysis,
a significant linear relationship was established between LD50
and the antinociceptive ED50 of 12 diterpenoid alkaloids, and
it was hypothesized that the analgesic effects of these alkaloids
were secondary to their toxic effects (Bello-Ramirez and Nava-
Ocampo, 2004a), although there has been no evidence for a
causal relationship between them.
However, we recently discovered that bulleyaconitine A anti-
hypersensitivity can be separated from its neurotoxicity by
the mechanism of action. The microglial inhibitor minocycline
(Raghavendra et al., 2003; Hua et al., 2005) completely
abolished the antinociceptive effects of bulleyaconitine A (but
not dynorphin A or the sodium channel blocker bupivacaine) in
neuropathic rats, but did not significantly affect bulleyaconitine
A neurotoxicity. Treatment with bulleyaconitine A significantly
increased the dynorphin A level (both the gene expression and
peptide content) in the spinal cord and cultured primary spinal
microglia (but not astrocytes or neurons) from neonatal and
adult rats, which was completely attenuated by minocycline.
In contrast, the sodium channel blockers bupivacaine and
lidocaine did not stimulate dynorphin A expression or inhibit
the stimulatory effects of bulleyaconitine A on the dynorphin
A expression in spinal microglia (Li et al., 2016). It is not
known whether the C8-acetylester and C14-benzoylester groups
are responsible for aconitine’s stimulation on spinal microglial
dynorphin A expression and subsequent anti-hypersensitivity in
neuropathic pain.
Abbreviations: ANOVA, analysis of variance; Emax, maximum effect;
EC50, median effective concentration; ED50, median effective dose; gapdh,
glyceraldehyde-3-phosphate dehydrogenase; LD50, median lethal dose; % MPE, %
maximum possible effect; nor-BNI, nor-binaltorphimine dihydrochloride; OX42,
microglia marker; PCR, polymerase chain reaction; TD50, median toxic dose.
As a foremost highly toxic plant with marked effects on the
central nervous and cardiovascular systems, Aconitum exhibits
a narrow therapeutic window, which brings challenges to safe
use as a medicine. From a standard approach of traditional
Chinese medicine, Aconitum must be generally processed by
heating in boiling or steaming water, or treating with a
dilute acid or alkali solution for a few hours, to reduce the
toxicity before it can be used in medicine or in the herbal
commercial market. It has been demonstrated that the processing
of Aconitum dramatically deacetylates diester aconitines (such
as aconitine, mesaconitine, and hypaconitine) at the C8 to
form monoester diterpene alkaloid benzoylaconines, for instance,
benzoylaconine, benzoylmesaconine, and benzoylhypaconine.
These monoesters are further debenzoylated at the C14 to form
hydramine-type aconines, such as aconine, mesaconine, and
hypaconine (Gozuacik et al., 2003; Singhuber et al., 2009; Sun
et al., 2009; Lu et al., 2010). The two-step processing pathway
of the diester diterpenoid alkaloids represented by aconitine
is presented in Figure 1. Interestingly, the same metabolic
pathway as physical processing also takes place in the living
body. The concentration of aconitine is decreased, whereas the
concentrations of benzoylaconine and aconine are increased, in
the blood and body organs including the liver and kidneys in
mice (Wada et al., 2005), rats (Wang et al., 2006), and humans
(Zhang et al., 2005). The metabolism of Aconitum alkaloids is
mainly carried out by carboxylesterases (Zhang et al., 2015).
Although the antinociceptive properties of aconitines, from
the perspective of the mechanism of action, can be separated
from their toxicity (Li et al., 2016), their analgesic effects are
closely associated with the toxicity and cannot be separated. This
raises questions that whether the process makes scientific sense if
the procedure does not differentially reduce the antinociceptive
and toxic effects of Aconitum and its derived aconitines. It was
reported that all three deacetylated metabolites, benzoylaconine,
benzoylmesaconine, and benzoylhypaconine, inhibited acetic
acid–induced writhing responses, with activities roughly 100-
fold less than those of their parent compounds aconitine,
mesaconitine, and hypaconitine (Hikino et al., 1979). It was also
summarized from the literature that the LD50 values of aconitine,
benzoylaconine, and aconine administered by intravenous
injection in mice were 0.12, 23, and 120 mg/kg, respectively
(Mizugaki and Ito, 2005). However, to our knowledge, no direct
head-to-head comparative study has been performed to compare
aconitines and their hydrolyzed products benzoylaconines and
aconines on antinociception and neurotoxicity. It is important
to address the issue, particularly when the new hypothesis of
dynorphin A expression is in consideration.
Therefore, we aimed to study the mechanism that underlies
the antinociceptive effects of aconitine and its hydrolyzed
products benzoylaconine and aconine, and to elucidate
their differential effects on spinal microglial dynorphin A
expression, antinociception, and acute neurotoxicity. The
experimental procedures included the determination of (1) the
anti-hypersensitivity effects of aconitine, benzolyaconine, and
aconine in a rat model of neuropathy induced by tight ligation of
spinal nerves; (2) the blockade effects of the specific antiserum
against dynorphin A, selective κ-opioid receptor antagonist,
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FIGURE 1 | Illustration of the aconitine detoxification process by the two-step ester hydrolysis.
and microglial inhibitor on aconitine and benzolyaconine
antinociception; (3) the stimulatory effects of aconitine,
benzolyaconine, and aconine on dynorphin A expression in
primary cultures of microglia originating from the spinal cord;
(4) and the acute neurotoxicity of aconitine, benzoylaconine,
and aconine in neuropathic rats. The dose-response analysis was
particularly used in all tests for quantitative assessment of their
differential effects.
MATERIALS AND METHODS
Drugs and Reagents
Aconitine was obtained from Guokang Bio-Pharmaceutical
(Baoji, China), and benzolyaconine and aconine were purchased
from Nanjing Zelang Bio-Pharmaceutical (Nanjing, China).
Their molecular masses were confirmed by in-house mass
spectroscopy, and their purity was greater than 98% as
determined by the manufacturers using high-performance
liquid chromatography. Nor-binaltorphimine (nor-BNI) and
minocycline were purchased from Abcam (Cambridge, U.K.)
and Yuanye Biotech (Shanghai, China), respectively. The rabbit
polyclonal antibody neutralizing dynorphin A was purchased
from Phoenix Pharmaceuticals (Burlingame, CA, USA). Based on
the manufacturer’s information, the dynorphin A antiserum was
specific to dynorphin A (100%), but not to dynorphin B (0%),
β-endorphin (0%), α–neo-endorphin (0%), or leu-enkephalin
(0%). Its specificity was also validated by the antigen absorption
test by other laboratories (Wakabayashi et al., 2010; Yamada et al.,
2013).
Experimental Animals
Male adult (200 ± 20 g body weight) and 1-day-old neonatal
Wistar rats were obtained from the Shanghai Experimental
Animal Institute for Biological Sciences (Shanghai, China). The
rats were caged in a group of four with thick sawdust bedding
at standard room temperature, under a 12-h/12-h reversed light-
dark cycle (7:00 AM to 7:00 PM) at a constant temperature of
22◦C ± 2◦C. The adult rats received food and water ad libitum
and were acclimatized to the laboratory environment for 3–5 days
before the experiments. The experimental study groups (six rats
per group except for the neurotoxicity study, which had 10
rats per group) were randomly assigned, and the researcher was
blind to the results of the behavior tests. The research protocols
were approved by the Animal Care and Welfare Committee of
Shanghai Jiao Tong University.
Primary Microglial Cell Culture
Glial cells were isolated from the 1-day-old neonatal rats. The
isolated spinal cords were minced and then incubated with
trypsin. Dissociated cells were suspended in 75-cm2 tissue culture
flasks (1 × 107 cells/flask) precoated with poly-L-lysine and
maintained in a 5% CO2 incubator at 37◦C. After culture for
10 days, the microglial cells were prepared as floating cell
suspensions by shaking the flask at 260 rpm for 2 h. The aliquots
were transferred to plates, and the unattached cells were removed
by washing with serum-free Dulbecco’s modified Eagle’s medium.
The harvested microglia exhibited purity greater than 95% as
determined by CD11b (OX42) immunoreactivity.
RNA Extraction, Reverse Transcription,
and Real-Time Quantitative Polymerase
Chain Reaction
RNA extraction, reverse transcription, and real-time quantitative
PCR were performed as previously described (Chen et al.,
2012). The spinal lumbar enlargements of rats were
collected and mechanically homogenized with an electronic
microhomogenizer at 4,000 rpm for 10 s in TRIzol on ice. Total
RNA from the spinal lumbar enlargements were isolated using
TRIzol reagent (Invitrogen, Grand Island, NY, USA). A 1-µg
sample of total RNA was reverse-transcribed with a ReverTra
Ace qPCR RT-Kit (Toyobo, Japan). Real-time quantitative PCR
was carried out with the Mastercycler ep realplex (Eppendorf,
Germany) using the RealmasterMix (SYBR Green I) (Toyobo).
The fold change was calculated with the 2−11Ct method after
normalization to the gene of gapdh. The primers used were:
5′-CCA AGG TCA TCC ATG ACA AC-3′ (gapdh forward),
5′-TCC ACA GTC TTC TGA GTG GC-3′ (gapdh reverse)
(Gong et al., 2014), 5′-ACT GCC TGT CCT TGT GTT CC-3′
(prodynorphin forward), and 5′-CCA AAG CAA CCT CAT TCT
CC-3′ (prodynorphin reverse) (Leitl et al., 2014).
Intrathecal Catheterization and Injection
in Rats
An 18-cm polyethylene catheter (PE-10: 0.28-mm inner diameter
and 0.61-mm outer diameter, Clay Adams, Parsippany, NJ, USA)
with a volume of 13 µL was inserted into the lumbar level
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of the spinal cord as described elsewhere under inhalational
isoflurane anesthesia (4% for induction and 1% for maintenance)
run by an anesthesia meter (Ugo Basile Gas Anesthesia System,
Comerio, Italy). Two days after recovery from anesthesia, the
placement of the catheter in the spinal cord was verified by
administration of 4% lidocaine (10 µL, followed by 15 µL of
saline for flushing). Rats that had no motor impairment after
placement of the intrathecal catheter were considered for the
study, and rats that developed immediate bilateral paralysis of
the hindlimbs after intrathecal administration of lidocaine were
selected for the study. For intrathecal administration of the
control and test articles, 10 µL of each drug was injected with
a 50-µL microinjector (Shanghai Anting Micro-Injector Factory,
Shanghai, China) and was flushed with 15 µL of normal saline
solution.
Rat Model of Neuropathic Pain
To induce hypersensitivity to neuropathic pain, the rats were
subjected to spinal nerve ligation as previously described Kim
and Chung (1992) and Zhang et al. (2013). Unilateral ligation of
the L5 and L6 spinal nerves was performed under inhalational
isoflurane anesthesia (4% for induction and 1% for maintenance)
run by an anesthesia meter (Ugo Basile Gas Anesthesia System).
The left L5 and L6 spinal nerves were isolated and tightly ligated
with 6-0 silk thread. After ligation, the wound was sutured and
the rats were returned to their home cages for recovery. After
spinal nerve ligation, only those rats with marked unilateral
allodynia to mechanical stimulation (i.e., a hindpaw withdrawal
threshold of less than 8 g on the operated side) and with no major
impairment were included in the study. Drug testing started
2–4 weeks after spinal nerve ligation.
Behavioral Assessments of Mechanical
Allodynia and Heat Hyperalgesia in Rats
To evaluate mechanical allodynia, the animals were acclimatized
for at least 30 min to the test environment, namely, a plexiglass
box on a metal grid (0.5 cm × 0.5 cm). The hindpaw withdrawal
threshold was measured with a 2450 CE Electronic von Frey hair
(IITC Life Science Inc, Woodland Hill, CA, USA). An electronic
handheld transducer with a No. 15 monofilament was applied
perpendicularly to the medial surface of the hindpaws with
increasing force (ranging from 0.1 to 90 g) until the rat suddenly
withdrew or licked the hindpaw. The lowest force that produced
a withdrawal response was considered to be the threshold, which
was the mean of three repeated measurements made in a 5-min
interval.
To assess heat hyperalgesia, the rats were put in a plexiglass
box on an elevated glass surface. After an adaptation period of
at least 30 min, radiant heat was applied to the plantar medial
surface of each hindpaw. The hindpaw withdrawal latency was
measured with a Model 390G Plantar Test Analgesia Meter (IITC
Life Science Inc.). To prevent tissue damage, the latency cutoff
was set at 30 s. The paw withdrawal latency was defined as the
time from the onset of radiant heat application to the withdrawal
of the hindpaw. Both hindpaws were tested independently three
times with a 5-min interval between trials. The result for each test
was calculated as the mean of the three repeated measurements.
Rat Acute Neurotoxicity
The rats were observed for acute neurotoxicity after each
intrathecal injection of test articles, with a focus on motor
blockade effects and survival. Survival and abnormal motor-
blockade behaviors, including asthma, abdominal breathing,
locomotion difficulty, and paralysis, were continuously
monitored for 24 h after the treatment, with special attention
given during the first 4 h. Paralysis was defined as an inability
to negotiate a 60-degree inclined plane (Durant and Yaksh,
1986). Death was defined as respiratory arrest over a period of
5 min. The paralysis and mortality rates and their latencies were
quantitatively recorded and tabulated.
Statistical Analysis
The percentage of maximal possible effect (% MPE) was
calculated using the following formula: (postdrug threshold
in ipsilateral hindlimb – baseline threshold in ipsilateral
hindlimb)/(baseline threshold in contralateral hindlimb –
baseline threshold in ipsilateral hindlimb) × 100 (Bowersox
et al., 1996). A % MPE value near 100 indicates normal
mechanical thresholds (i.e., near contralateral thresholds), and
a value near 0 indicates allodynia. For the dose-response curve
analysis, the parameters (i.e., minimum effect; Emax, median
effective concentration or dose, or median toxic or lethal
dose [EC50, ED50, TD50, or LD50], and Hill coefficient [n])
were calculated from the individual dose-response curves using
the Prism program (version 5.01, GraphPad Software, San
Diego, CA, USA). To determine the parameters of the dose-
response curves, the values of response (Y) were fitted by
non-linear least-squares curves to the relation Y = a + bx,
where x = [D]n/(ED50n + [D]n), [C]n/(EC50n + [C]n),
[D]n/(TD50n + [D]n) or [D]n/(LD50n + [D]n), to give each value
of ED50, EC50, TD50, or LD50 and b (Emax) yielding a minimum
residual sum of squares of deviations from the theoretical curve
(Wang and Pang, 1993).
The data are presented as the mean ± standard error of
the mean (SEM) or with 95% confidence limits, and no data
were missing. Statistical significance was evaluated by two-way
repeated-measures ANOVA, which was followed by a post hoc
Student–Newman–Keuls test when a statistically significant drug
(dose) effect was observed with factors of drug (dose), time,
and their interaction. Probability values were two-tailed, and the
statistical significance criterion (P-value) was 0.05.
RESULTS
Anti-hypersensitivity Effects of
Aconitine, Benzolyaconine, and Aconine
The anti-hypersensitivity effects of aconitine, benzolyaconine,
and aconine were studied in rats with neuropathy induced by
spinal nerve ligation. Six groups of neuropathic rats received
a single intrathecal bolus injection of normal saline solution
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FIGURE 2 | Antinociceptive effects of intrathecal administration of
aconitine on mechanical allodynia (A) and heat hyperalgesia (B) in
spinal L5/L6 nerve–ligated neuropathic rats. Rats received a single
intrathecal administration of saline solution and aconitine (1, 3, 10, 30, and
100 ng). Withdrawal responses to mechanical and thermal stimuli in the
contralateral and ipsilateral hindpaws were consecutively measured with
10-min intervals. Data are presented as the mean ± SEM (six per group).
(10 µL) or aconitine (1, 3, 10, 30, or 100 ng). The withdrawal
thresholds to von frey monofilaments and withdrawal latency
to radiant heat were consecutively measured (at an interval of
10 min) in both the contralateral and ipsilateral paws before
and 30, 60, 120, and 240 min or 40, 70, 130, and 250 min
after injection. As shown in Figures 2A,B, tight ligation of
the L5 and L6 spinal nerves produced marked mechanical
allodynia and heat hyperalgesia in the ipsilateral paws. The
paw withdrawal responses remained unchanged during the 4-h
observation period in rats treated with saline solution. Aconitine
administered by intrathecal injection did not significantly alter
the withdrawal responses in the contralateral paws, but it
remarkably alleviated mechanical allodynia and heat hyperalgesia
in the ipsilateral paws in a time-dependent manner, with a peak
effect at 1 h after injection.
The anti-hypersensitivity effect of aconitine was dose-
dependent. The % MPE values were calculated from each dose of
aconitine at 1 h after injection, and the dose-response curves were
projected. For the blockade of mechanical allodynia, the Emax
and ED50 values were 61.9% MPE and 25.2 ng or 39.0 pmol (95%
confidence limits: 18.8–33.8 ng or 29.1–52.3 pmol) (Figure 3A).
FIGURE 3 | Dose-inhibitory response curves of aconitine,
benzolyaconine, and aconine on mechanical allodynia (A) and heat
hyperalgesia (B) in spinal L5/L6 nerve–ligated neuropathic rats. %
Maximal possible effects of aconitine, benzolyaconine, and aconine were
calculated 1 h after injection from original data of Figures 2, 4, and 5. The
dose-response analyses were best projected by the non-linear least-squares
method.
For the blockade of thermal hyperalgesia, the Emax and ED50
values were 100% MPE and 20.5 ng or 31.7 pmol (95% confidence
limits: 13.4–31.4 ng or 20.8–48.6 pmol) (Figure 3B).
Five groups of neuropathic rats received a single intrathecal
bolus injection of normal saline solution (10 µL) or
benzolyaconine (0.3, 1, 3, or 10 µg). In the ipsilateral paws,
intrathecal injection of benzolyaconine alleviated the mechanical
allodynia and heat hyperalgesia in a dose- and time-dependent
manner (P < 0.05 by two-way ANOVA). Benzolyaconine
did not significantly affect the paw withdrawal responses in
the contralateral paws (Figures 4A,B). The % MPE values
were calculated from each dose of benzolyaconine at 1 h after
injection, and the dose-response curves were projected. The
Emax and ED50 values for anti-allodynia were 56.4% MPE
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FIGURE 4 | Antinociceptive effects of intrathecal administration of
benzolyaconine on mechanical allodynia (A) and heat hyperalgesia (B)
in spinal L5/L6 nerve–ligated neuropathic rats. Rats received a single
intrathecal administration of saline solution and benzolyaconine (0.3, 1, 3, and
10 µg). Withdrawal responses to mechanical and thermal stimuli in the
contralateral and ipsilateral hindpaws were consecutively measured with
10-min intervals. Data are presented as the mean ± SEM (six per group).
and 2.2 µg or 3.6 nmol (95% confidence limits: 1.6–3.2 µg or
2.6–5.2 nmol) (Figure 3A). Accordingly, the Emax and ED50
values for anti-hyperalgesia were 100% MPE and 2.1 µg or
3.5 nmol (95% confidence limits: 1.5–3.0 µg or 2.5–5.0 nmol)
(Figure 3B).
Three groups of neuropathic rats received a single intrathecal
bolus injection of normal saline solution (10 µL) or aconine (100
or 300 µg). The highest dose of 300 µg was selected due to that
a higher dose might lead to obvious motor-blockade behaviors
or death. As shown in Figures 5A,B, intrathecal injection of
aconine up to 300 µg did not produce significant anti-allodynia
or anti-hyperalgesia in the ipsilateral paws, nor did it significantly
affect the paw withdrawal responses in the contralateral paws.
The % MPE of aconine at 1 h after injection are also presented
in Figures 3A,B on mechanical allodynia and heat hyperalgesia.
Table 1 summarizes the ED50 values in mole base
for aconitine, benzolyaconine, and aconine to block pain
hypersensitivity. Because anti-allodynia and anti-hyperalgesia
were closely correlated, their ED50 values were averaged to obtain
a normalized ED50 for anti-hypersensitivity. The ED50 ratios for
FIGURE 5 | Effects of intrathecal administration of aconine on
mechanical allodynia (A) and heat hyperalgesia (B) in spinal L5/L6
nerve–ligated neuropathic rats. Rats received a single intrathecal
administration of saline solution and aconine (100 and 300 µg). Withdrawal
responses to mechanical and thermal stimuli in the contralateral and ipsilateral
hindpaws were consecutively measured with 10-min intervals. Data are
presented as the mean ± SEM (six per group).
aconitine and benzolyaconine to block mechanical allodynia and
heat hyperalgesia were 1:92 and 1:110, with a normalized ED50
ratio of 1:102.
Blockade Effects of the Dynorphin A
Antiserum, Nor-BNI, and Minocycline on
Aconitine and Benzolyaconine
Anti-allodynia
To test whether aconitine produced anti-allodynia through
dynorphin A expression in the spinal cord, the specific dynorphin
A antiserum (Fan et al., 2015) and selective κ-opioid receptor
antagonist nor-BNI (Beardsley et al., 2010) were applied. Four
groups of spinal nerve–ligated neuropathic rats received a single
intrathecal injection of 10 µL saline solution, 10 µL blank
rabbit serum (1:10 dilution), 10 µL dynorphin A antiserum (1:10
dilution), or nor-BNI (100 µg). A 100-ng dose of aconitine was
given by intrathecal injection 0.5 h after the first injection. The
dose and time regimens of the dynorphin A antiserum and
nor-BNI were selected based on previous reports (Fan et al.,
2015; Fan et al., 2016; Li et al., 2016). The paw withdrawal
Frontiers in Pharmacology | www.frontiersin.org 6 October 2016 | Volume 7 | Article 367
fphar-07-00367 October 5, 2016 Time: 11:15 # 7
Li et al. Aconitine on Dynorphin A Expression, Antinociception and Neurotoxicity
TABLE 1 | The median effective dose (ED)50, toxic dose (TD)50 (for flaccid paralysis), and lethal (LD)50 and their normalized values, and the therapeutic
index values for aconitine, benzolyaconine, and aconine given by intrathecal injection to produce anti-hypersensitivity and acute neurotoxicity in spinal
nerve-ligated neuropathic rats (6 and 10 per group for the anti-hypersensitivity and neurotoxicity studies, respectively).
Compound Anti-hypersensitivity (ED50) Toxicity (TD50 or LD50) Therapeutic Index
Allodynia Hyperalgesia Normalized Paralysis Mortality Normalized TD50/ED50 LD50/ED50 Normalized
Aconitine 39 pmol 32 pmol 35 pmol 0.4 nmol 0.6 nmol 0.5 nmol 10:1 19:1 14:1
Benzolyaconine 3.6 nmol 3.5 nmol 3.6 nmol 0.2 µmol 0.2 µmol 0.2 µmol 56:1 57:1 56:1
Aconine NA NA NA 1.5 µmol 1.7 µmol 1.6 µmol NA NA NA
Aconitine/Benzoyl-Aconine 1:92 1:110 1:102 1:452 1:421 1:400
Benzolyaconine/Aconine NA NA NA 1:8 1:7 1:8
Aconitine/Aconine NA NA NA 1:3,750 1:2,833 1:3,200
NA, not applicable.
responses to mechanical stimuli were measured before, and
0.5, 1, 2, and 4 h after the second administration. As shown
in Figure 6A, intrathecal injection of aconitine produced a
marked and reversible anti-allodynic effect in the ipsilateral paws.
Although intrathecal injection of the antiserum and nor-BNI did
not affect the withdrawal responses in either the contralateral
or ipsilateral paws as compared to the saline solution control,
they completely blocked aconitine-induced anti-allodynia in the
ipsilateral paws (P < 0.05 by two-way ANOVA followed by the
post hoc Student–Newman–Keuls test).
To test whether aconitine produced anti-allodynia by
means of spinal microglia, the microglial inhibitor minocycline
(Raghavendra et al., 2003; Hua et al., 2005) was applied.
Two groups of neuropathic rats received two intrathecal
injections of saline solution (10 µL) + aconitine (100 ng),
and minocycline (100 µg) + aconitine (100 ng), respectively.
The second treatment was administered 4 h after the first
treatment. The dose and time regimens of minocycline were
selected according to the previous papers (Gong et al., 2014;
Fan et al., 2015, 2016). The paw withdrawal thresholds
for the response to mechanical stimuli were measured
before, and 0.5, 1, 2, or 4 h after the second treatment.
Intrathecal injection of minocycline did not affect withdrawal
thresholds in either the contralateral or ipsilateral paws
compared with the saline control. In the ipsilateral paws, a
single intrathecal injection of aconitine led to marked and
reversible anti-allodynia, which was completely prevented
by pretreatment with minocycline (P < 0.05 by two-way
ANOVA followed by the post hoc Student–Newman–Keuls test)
(Figure 6B).
To test whether the stimulatory effect of benzolyaconine on
spinal dynorphin A expression was also causally associated with
its anti-allodynia, the same treatment regimens of dynorphin
A antiserum, nor-BNI, and minocycline on benzolyaconine
were applied in six groups of neuropathic rats in the two
separate studies. As shown in Figure 7, intrathecal injection
of benzolyaconine (10 µg) produced marked and reversible
anti-allodynia in the ipsilateral paws. Pretreatment with the
dynorphin A antiserum (Figure 7A), nor-BNI (Figure 7A), and
minocycline (Figure 7B) completely alleviated benzolyaconine
anti-allodynia (P< 0.05 by two-way ANOVA followed by the post
hoc Student–Newman–Keuls test).
Stimulatory Effects of Aconitine,
Benzolyaconine, and Aconine on the
Prodynorphin Gene Expression in
Cultured Primary Spinal Microglia
Primary cultures of microglial cells taken from the spinal cords
of the neonatal rats were treated with a variety of concentrations
of aconitine (1 × 10−8, 3 × 10−8, 1 × 10−7, 3 × 10−7, and
1 × 10−6 M), benzolyaconine (3 × 10−7, 1 × 10−6, 3 × 10−6,
1 × 10−5, 3 × 10−5, and 1 × 10−4 M) and aconine (1 × 10−4,
3 × 10−4, 1 × 10−3, 3 × 10−3, and 1 × 10−2 M) for 2 h. As
the bulleyaconitine A-increased dynorphin A level measured by
the enzyme-linked immunosorbent assay was in parallel with the
prodynorphin gene expression in spinal microglia from neonatal
and adult rats (Li et al., 2016), the expression of the cellular
prodynorphin gene encoding dynorphin A was only measured
in this study using real-time quantitative PCR. As shown in
Figure 8, both aconitine and benzolyaconine concentration-
dependently increased prodynorphin gene expression, with the
EC50 values of 32 nM and 3 µM, respectively. The EC50 ratio for
aconitine and benzolyaconine was 1:94. However, treatment with
aconine up to 10 mM did not significantly affect prodynorphin
gene expression.
Acute Spinal Neurotoxicity of Aconitine,
Benzolyaconine, and Aconine
To test the acute spinal neurotoxicity of aconitine, four
groups of spinal nerve–ligated neuropathic rats received a
single intrathecal bolus injection of aconitine (0.25, 0.32, and
0.4 µg). Abnormal behavior and survival were immediately
observed for 24 h, with special attention given to the first
4 h. Intrathecal injection of aconitine evoked a range of
abnormal behavior related to motor blockade, including cyanosis,
asthma, abdominal breathing, locomotion difficulty, and flaccid
paralysis in particular. The toxic behavior was immediate (a
latency of 2–3 min), short-lasting (a duration of 5–10 min),
and closely associated with death. As shown in Figures 9A,B,
the flaccid paralysis and death were dose-dependent with a
very steep shape in their dose-response curves. The dose-
response analysis showed that the TD50 (for paralysis) and
LD50 values were 0.3 µg or 0.4 nmol (95% confidence limits:
0.2–0.3 µg or 0.4–0.5 nmol) and 0.4 µg or 0.6 nmol (95%
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FIGURE 6 | Blockade effects of intrathecal injection of the specific
dynorphin A antiserum (A), selective κ-opioid receptor antagonist
nor-BNI (A), and microglial inhibitor minocycline (B) on spinal aconitine
anti-allodynia in spinal L5/L6 nerve–ligated neuropathic rats. The
dynorphin A antiserum (1:10) and nor-BNI (100 µg) were given by intrathecal
injection 0.5 h earlier than the intrathecal aconitine (100 ng) treatment,
whereas minocycline (100 µg) was given 4 h earlier. Withdrawal responses to
mechanical stimuli were measured in the contralateral and ipsilateral
hindpaws. Data are presented as the mean ± SEM (six per group). ∗Denotes
statistical significance compared with the saline + aconitine group (P < 0.05
by two-way repeated-measures ANOVA followed by the post hoc
Student–Newman–Keuls test).
confidence limits: 0.4–0.4 µg or 0.6–0.6 nmol), respectively.
However, the onsets of aconitine to induce paralysis and death
were not dose-dependent, with paralysis latencies of 2.3 ± 0.7,
2.5 ± 0.8, and 2.6 ± 1.2 min and death latencies of 13.6,
12.4 ± 2.3, and 10.0 ± 3.3 min at 0.25, 0.32, and 0.4 µg,
respectively.
Three groups of neuropathic rats received a single intrathecal
bolus injection of benzolyaconine (100, 200, and 400 µg).
Intrathecal injection of benzolyaconine caused immediate (2–
3 min) and short-lasting (5–10 min) motor-blockade behavior,
including flaccid paralysis and associated death (Figures 9A,B).
The dose-response curve of benzolyaconine was less steep than
that of aconitine. The dose-response analysis showed that the
TD50 (for paralysis) and LD50 values were 117 µg or 0.2 µmol
(95% confidence limits: 101–135 µg or 0.2–0.2 µmol) and
FIGURE 7 | Blockade effects of intrathecal injection of the specific
dynorphin A antiserum (A), selective κ-opioid receptor antagonist
nor-BNI (A), and microglial inhibitor minocycline (B) on spinal
benzolyaconine anti-allodynia in spinal L5/L6 nerve–ligated
neuropathic rats. The dynorphin A antiserum (1:10) and nor-BNI (100 µg)
were given by intrathecal injection 0.5 h earlier than the intrathecal
benzolyaconine (10 µg) treatment, whereas minocycline (100 µg) was given
4 h earlier. Withdrawal responses to mechanical stimuli were measured in the
contralateral and ipsilateral hindpaws. Data are presented as the
mean ± SEM (six per group). ∗Denotes statistical significance compared with
the saline + benzolyaconine group (P < 0.05 by two-way repeated-measures
ANOVA followed by the post hoc Student–Newman–Keuls test).
142 µg or 0.2 µmol (95% confidence limits: 130–156 µg or 0.2–
0.3 µmol), respectively. The onsets of benzolyaconine to induce
paralysis and death were not dose-dependent, and the latency
values were similar to those of aconitine.
Three groups of neuropathic rats received a single intrathecal
bolus injection of aconine (500, 750, and 1,000 µg). Intrathecal
injection of aconine caused immediate and short-lasting motor-
blockade behavior, including flaccid paralysis and associated
death (Figures 9A,B). Analysis of the steep dose-response curves
showed that the TD50 (for paralysis) and LD50 values were
757 µg or 1.5 µmol (95% confidence limits: 562–1,021 µg or
1.1–2.0 µmol) and 862 µg or 1.7 µmol (95% confidence limits:
779–954 µg or 1.6–1.9 µmol), respectively. The onsets of aconine
at each dose were also independent of dose, with values similar to
those of aconitine and benzolyaconine.
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FIGURE 8 | Concentration-stimulatory response curves of aconitine,
benzolyaconine, and aconine on the prodynorphin gene expression in
primary cultures of spinal microglia. Microglial cells originating from the
spinal cords of the neonatal (1-day) rats were collected 2 h after incubation
with the test articles. The expression of the prodynorphin gene (encoding
dynorphin A) referred to the gapdh gene was measured with real-time
quantitative PCR. The concentration-response analyses were best projected
by the non-linear least-squares method. Data are presented as the
mean ± SEM (three per treatment with two repeats).
The TD50 (for paralysis) and LD50 values of aconitine,
benzolyaconine, and aconine in mole base are presented in
Table 1. Because death was closely associated with paralysis,
the LD50 and TD50 values for paralysis were averaged to obtain
a normalized TD50. The analysis showed that the TD50 (for
paralysis) and LD50 ratios for aconitine vs. benzolyaconine were
1:452 and 1:421, with a normalized TD50 ratio of 1:400. For
benzolyaconine vs. aconine, the TD50 (for paralysis) and LD50
ratios were 1:8 and 1:7, with a normalized TD50 ratio of 1:8. For
aconitine vs. aconine, the TD50 (for paralysis) and LD50 ratios
were 1:3750 and 1:2833, with a normalized TD50 ratio of 1:3200.
The therapeutic index values of aconitine and benzolyaconine
were also calculated. For aconitine, the TD50/ED50 (for paralysis)
and LD50/ED50 ratios were 10:1 and 19:1, with a normalized
TD50/ED50 ratio of 14:1. For benzolyaconine, the TD50/ED50
(for paralysis) and LD50/ED50 ratios were 56:1 and 57:1, with a
normalized TD50/ED50 ratio of 56:1.
DISCUSSION
We recently made a conceptual advancement and identified
that spinal microglial expression of dynorphin A is responsible
for bulleyaconitine A anti-hypersensitivity in animal models of
pain hypersensitivity, including formalin-induced tonic pain,
neuropathic pain, and bone cancer pain (Li et al., 2016). In
addition, Bullatine A, a C20-diterpenoid alkaloid, specifically
stimulated dynorphin A expression in microglia in the spinal
FIGURE 9 | Dose-response curves of intrathecal administration of
aconitine, benzolyaconine, and aconine on flaccid paralysis (A) and
death (B) in spinal L5/L6 nerve–ligated neuropathic rats. Rats received a
single intrathecal bolus injection of aconitine (0.25, 0.32, and 0.4 µg),
benzolyaconine (100, 200, and 400 µg), and aconine (500, 750, and
1,000 µg). Paralysis and survival were observed for 24 h, with special
attention given to the first 4 h. The dose-response analyses were best
projected by the non-linear least-squares method. Data are presented as the
percentage (10 per group).
cord and cultured primary microglia (Huang et al., 2016).
Dynorphin A is produced in many different parts of the brain,
including the hypothalamus, striatum, and hippocampus, and
in the spinal cord (Khachaturian et al., 1982; Smith and Lee,
1988; Mollereau et al., 1999). The expression and secretion of
dynorphin A have been found in neurons (Minokadeh et al.,
2010), astrocytes (Wahlert et al., 2013), and microglia (Li et al.,
2016). Dynorphin A is an endogenous opioid neurotransmitter
that modulates analgesic responses primarily by activation of
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the κ-opioid receptor located on neurons in the descending
inhibitory system, although it has some affinity for µ- and
δ-opioid receptors, and N-methyl-D-aspartic acid receptors
(Nahin et al., 1989; Faden, 1990; Vanderah et al., 1996; Schwei
et al., 1999; Rojewska et al., 2014). Our study further confirmed
the causal relationship of aconitine between dynorphin A
expression and antinociception, and suggest that the action of
aconitine-evoked dynorphin A is via the activation of neuronal
κ-opioid receptors. (1) Intrathecal injection of aconitine and
its hydrolyzed metabolite benzoylaconine, but not aconine,
markedly attenuated mechanical allodynia and heat hyperalgesia
in a rat model of neuropathy induced by tight ligation of
the spinal nerves. (2) The anti-allodynic effects of spinal
aconitine and benzoylaconine were completely prevented by
pretreatment with the specific dynorphin A antiserum, selective
κ-opioid receptor antagonist nor-BNI, and microglial inhibitor
minocycline. Minocycline has been extensively used to study
the role of microglia in experimental models of brain ischemia
(Yrjanheikki et al., 1999), traumatic brain injury (Sanchez Mejia
et al., 2001), and peripheral nerve injury-induced neuropathy
(Gong et al., 2014; Fan et al., 2015, 2016; Li et al., 2016).
Minocycline is generally considered to be a specific inhibitor
of microglia [but not astrocytes (Wu et al., 2002; Yoon et al.,
2012) or oligodendroglial progenitors (Zhang et al., 2003)], but
it was reported to have some direct biological effects in neurons
(Wilkins et al., 2004; Huang et al., 2010). Although we also
demonstrated that aconitine and benzoylaconine stimulated the
prodynorphin gene expression in cultured primary microglial
cells, studies are needed to provide more valid in vivo evidence
of the microglial origin of dynorphin A, by applications of
additional chemicals (such as liposome clodronate or PLS3397)
and genetical manipulation. (3) Treatment with aconitine and
benzoylaconine, but not aconine, significantly stimulated the
expression of prodynorphin gene (encoding dynorphin A) in
primary cultures of spinal microglial cells. In addition, we have
previously shown that the aconitine analog bulleyaconitine A
also stimulated the prodynorphin gene expression and increased
the dynorphin A level in cultured primary microglial cells (but
not astrocytes or neurons) from neonatal and adult rats, and
the spinal cord of neuropathic rats in vivo, which was totally
inhibited by pretreatment with minocycline (Li et al., 2016).
Furthermore, the anti-hypersensitivity effects of the processed
Aconitum extracts were also mediated by the stimulation of
dynorphin A release and the activation of spinal κ-opioid
receptors in rodent models of chronic constriction injury
and repeated cold stress (Omiya et al., 1999; Suzuki et al.,
1999; Xu et al., 2006). These results suggest that Aconitum
and its contained diester diterpenoid aconitines cause anti-
hypersensitivity primarily by stimulating the spinal microglial
expression of dynorphin A, which passes the microglial neuronal
synapses to activate κ-opioid receptors located on postsynaptic
neurons.
The activity of aconitine on the stimulation of microglial
dynorphin A expression (EC50 of 32 nM) appears to be more
potent than bulleyaconitine A (EC50 of 45 nM) by approximately
0.5-fold. The greater potency of aconitine is also supported
by the lower ED50 values of 39 and 32 pmol for intrathecal
aconitine to block mechanical allodynia and heat hyperalgesia,
which were approximately three to four times less than those
(180 and 201 pmol) of bulleyaconitine A, respectively (Li
et al., 2016). Being the C19-diterpenoid alkaloids, aconitine and
bulleyaconitine A share similar structures, only with the major
difference of two hydroxyl groups being attached at the C3 and
C15 of aconitine (Li et al., 2016). This suggests that hydroxylation
helps aconitines to increase the expression of spinal microglial
dynorphin A and subsequent antinociception. The findings are
consistent with the previous findings in acute pain. Yunaconitine
has a C3-hydroxyl group, whereas bulleyaconitine A does not,
and the C3-hydroxyl group of 3-acetylaconitine is acetylated.
Systemic yunaconitine produced greater antinociception than
bulleyaconitine A and 3-acetylaconitine in acetic acid and
formalin tests (Yu et al., 1996).
Intrathecal benzolyaconine was able to block mechanical
allodynia and heat hyperalgesia in neuropathy in a dose-
dependent manner, but their normalized ED50 value (3.6 nmol)
was 102 times greater than that of aconitine (35 pmol).
More specifically, treatment with benzolyaconine increased the
dynorphin A expression in cultured primary spinal microglial
cells with an EC50 of 3 µM, which was also 94 times greater
than that of aconitine (32 nM). These results indicate that the
C8-acetylester group accounts for the effects of aconitine on the
spinal microglial dynorphin A production and antinociception
by the same degrees, which further support the concept that
spinal microglial dynorphin A expression mediates aconitine-
induced antinociception. The lesser potency of benzolyaconine
in antinociception is also supported by the indirect evidence
from other laboratories. It has been reported that benzoylaconine,
benzoylmesaconine, and benzoylhypaconine inhibited acetic
acid-induced writhing responses, with activities of around 100
times less than those of their parent compounds aconitine,
mesaconitine, and hypaconitine (Hikino et al., 1979). It was
also reported that the ED50 values for subcutaneous 3,15-
diacetylbenzoylaconine (with the acetyl groups at both the C3
and C15) antinociception in the acetic acid, electric shock,
and hot-plat assays were 12–16 times greater than those of 3-
acetylaconitine (with the acetyl groups at both the C3 and C8)
in mice and 25–30 times greater in rats (Zheng et al., 1994).
Intrathecal administration of aconitine produced acute
neurotoxicity characterized by motor block-related flaccid
paralysis and death, with a normalized TD50 of 0.5 nmol and
a narrow therapeutic index (TD50/ED50) of 14:1. In contrast,
the normalized therapeutic index of benzoylaconine was 56:1,
reflecting the fact that deacetylation of the precursor aconitine
more effectively reduces neurotoxicity than antinociception by
three fold. The differential effect of deacetylation on neurotoxicity
is also supported by the indirect evidence that the therapeutic
index values of 3,15-diacetylbenzoylaconine by subcutaneous
and intracerebroventricular injection were 0.4- to 0.9-fold and
three-fold higher, respectively, than those of 3-acetylaconitine
(Zheng et al., 1994). These results suggest that benzoylaconines,
as secondary plant metabolites, may be prodrug candidates for
the development of analgesics, given that primary aconitines,
including bulleyaconitine A, 3-acetylaconitine, yunaconitine,
and lappaconitine, have already been used as analgesics in
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clinical practice. The differential effects of aconitine and
benzoylaconine on antinociception and toxicity also provide a
scientific rationale for the Aconitum processing, which aims
principally to decompose the diester diterpenoid aconitines into
the relatively less toxic monoester diterpenoid benzoylaconines
(Gozuacik et al., 2003; Singhuber et al., 2009; Sun et al.,
2009; Lu et al., 2010). It has been reported that steaming
of Aconitum at 120◦C for 10 and 120 min resulted in
90.4 and 99.8% reduction of aconitine, and enhancement of
benzolyaconine by 4.5- and 7.9-fold, respectively. Baking of
Aconitum at 150◦C for 10 and 120 min produced similar
results with less degree, by 85.7 and 95.9% decreases in
aconitine and enhancement of benzolyaconine by 3.0- and 4.1-
fold, respectively (Yang et al., 2014). The processed Aconitum
contains a mixture of bioactive aconitines and benzoylaconines,
both of which contribute to certain extent to its analgesia
(Hikino et al., 1979). Thus, the benzoylaconine-increased
TD50/ED50 makes the processed Aconitum a more favorable
analgesic, which is further enriched by the in vivo hydrolysis
in the body. It was reported that blood benzoylaconines
were increased and aconitines were decreased after oral
administration of the processed Aconitum due to acetylester
hydrolysis by carboxylesterases located in the gastrointestinal
tract, intestinal bacteria, blood, and liver (Zhang et al.,
2015).
Treatment with aconine up to 10 mM did not significantly
stimulate the dynorphin A expression, which is associated
with the finding that intrathecal injection of aconine up
to 300 µg did not alter mechanical allodynia or thermal
hyperalgesia in neuropathic rats. In contrast, intrathecal aconine
caused dose-dependent acute neurotoxicity, with a normalized
TD50 of 810 µg (1.6 µmol), which was seven times greater
than that of benzoylaconine (0.2 µmol). Our results suggest
that the C14-benzoly group is also required for aconitines
to stimulate spinal microglial dynorphin A expression and
associated antinociception, although it is less needed for
neurotoxicity. The differential effects of benzolyaconine and
aconine on antinociception and neurotoxicity further support the
hypothesis that the antinociception induced by aconitines can be
separated from their toxicity, the latter of which is presumably
caused by the interactions with neuronal sodium channels
(Ameri, 1998; Chan, 2009) and other possible mechanisms. In
contrast, during the processing of Aconitum, the first step is to
deacetylate at C8, but the second step of the debenzoylation at
C14 is also inevitably involved, particularly when the procedures
are overdone, although the benzoyl group is much more
resistant to hydrolysis than the acetyl group, probably due
to the mechanism of acyl migrations (Lerosen and Smith,
1949). The processed Aconitum mostly includes aconitines,
benzoylaconines, and aconines (Huang et al., 2007). It was
reported that steaming of Aconitum for 10 and 120 min led to
increase in the aconine content by 1.5- and 10.3-fold, respectively
(Yang et al., 2014). As we have demonstrated that benzolyaconine
is antinociceptive with a favorable profile, whereas aconine is not
antinociceptive but has certain toxicity (in contrast to the well-
assumed “non-toxic”), measures should be cautionally made to
avoid the overprocessing of Aconitum and excess hydrolysis of
benzolyaconine to form aconine.
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